Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

BioVaxys Technology Corp. C.BIOV

Alternate Symbol(s):  BVAXF

BioVaxys Technology Corp. is a Canada-based clinical-stage biopharmaceutical company. The Company is focused on improving patient lives with novel immunotherapies based on the DPX immune-educating technology platform and its HapTenix neoantigen tumor cell construct platform, for treating cancers, infectious disease, antigen desensitization and other immunological fields. The Company's clinical-stage pipeline includes maveropepimut-S, which is in phase II clinical development for advanced Relapsed-Refractory Diffuse Large B Cell Lymphoma (DLBCL) and platinum resistant ovarian cancer, and BVX-0918, a personalized immunotherapeutic vaccine using its HapTenix neoantigen tumor cell construct platform for treating refractive late-stage ovarian cancer. The Company is also leveraging its expertise in tumor immunology by creating a unique library of T-lymphocytes and other datasets post-vaccination with its personalized immunotherapeutic vaccines to identify new targetable tumor antigens.


CSE:BIOV - Post by User

Comment by frankmanon Dec 20, 2024 11:27am
38 Views
Post# 36372255

RE:RE:I still expect 50 to 100 percent increase in stock rice

RE:RE:I still expect 50 to 100 percent increase in stock riceHideaway absolutely agree. In the early days though they did have temporary corroboration with Merck. They only had two vaccines then. With DPX the products are almost endless. And they do have interested parties. As far as promotion goes he has been the same way since inception, as all of 2024 with about thirty or so press releases. He once told me he wanted to increase exposure to the Canadian market more then switched pr firms.
 
I believe some of the trading volume is sellers interested in the pp. The major goal of a CEO as you know is to raise capital and as they do not want another IMV. You’re right of course, as they need collaboration(s) and multiple revenue streams. What I can tell you though there is many more industry eyes this year and going forward after the acquisition.  
<< Previous
Bullboard Posts
Next >>